Ben Buelow

Advanced Cell Diagnostics (United States) — United States

Medicine · Health Sciences

15h-index839citations46works0.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Monoclonal and Polyclonal Antibodies Research(26), CAR-T cell therapy research(26), Biosimilars and Bioanalytical Methods(10), Multiple Myeloma Research and Treatments(8), Glycosylation and Glycoproteins Research(4)

Publications45 total

820 Discovery of a novel CD123 x gamma delta T cell engager for the treatment of acute myeloid leukemia
Regular and Young Investigator Award Abstracts·2025Open Access
Inhibition of CD38 enzyme activity on engrafted human immune cells enhances NAD+ metabolism and inhibits inflammation in an in-vivo model of xeno-GvHD
Frontiers in Immunology·2025· 1 citedOpen Access
Double Step-up Dosing (2SUD) Regimen Mitigates Severe Icans and CRS While Maintaining High Efficacy in Subjects with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (NHL) Treated with AZD0486, a Novel CD19xCD3 T-Cell Engager (TCE): Updated Safety and Efficacy Data from the Ongoing First-in-Human (FIH) Phase 1 Trial
Blood·2023· 17 cited
S224: HIGH COMPLETE RESPONSE RATE WITH TNB-486, A NOVEL CD19XCD3 T-CELL ENGAGER, IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: INTERIM RESULTS FROM AN ONGOING PHASE 1 STUDY
HemaSphere·2023· 2 citedOpen Access
High complete response rate with TNB-486 in relapsed/refractory follicular lymphoma: Interim results from an ongoing phase 1 study.
Journal of Clinical Oncology·2023· 9 cited
HIGH COMPLETE RESPONSE RATE WITH TNB‐486, A NOVEL CD19XCD3 T‐CELL ENGAGER, IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: INTERIM RESULTS FROM AN ONGOING PHASE 1 STUDY
Hematological Oncology·2023· 1 citedOpen Access
Interim Results of the Phase 1 Study of Tnb-486, a Novel CD19xCD3 T-Cell Engager, in Patients with Relapsed/Refractory (R/R) B-NHL
Blood·2022· 16 citedOpen Access
A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma
Journal of Clinical Oncology·2022· 115 citedOpen Access
A T-cell engaging bispecific antibody with a tumor-selective bivalent folate receptor alpha binding arm for the treatment of ovarian cancer
OncoImmunology·2022· 16 citedOpen Access
Abstract 6244: A T cell engaging bispecific antibody utilizing a bivalent tumor-selective folate receptor alpha binding arm for the treatment of ovarian cancer
Cancer Research·2022
A Phase 1 First-in-Human Study of Tnb-383B, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in Patients with Relapsed/Refractory Multiple Myeloma
Blood·2021· 48 cited
Attenuating CD3 affinity in a PSMAxCD3 bispecific antibody enables killing of prostate tumor cells with reduced cytokine release
Journal for ImmunoTherapy of Cancer·2021· 65 citedOpen Access
TNB585.001: A multicenter, phase 1, open-label, dose-escalation and expansion study of tnb-585, a bispecific T-cell engager targeting PSMA in subjects with metastatic castrate resistant prostate cancer.
Journal of Clinical Oncology·2021· 9 cited
Initial Results of a Phase I Study of TNB-383B, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in Relapsed/Refractory Multiple Myeloma
Blood·2020· 52 cited
Ex vivo efficacy of BCMA‐bispecific antibody TNB‐383B in relapsed/refractory multiple myeloma
eJHaem·2020· 21 citedOpen Access
A CD3 x FRα T-cell engaging bispecific antibody for efficient killing of ovarian cancer cells with minimal cytokine release.
Journal of Clinical Oncology·2020· 1 cited
Effect of modulation of CD3 binding in a PSMAxCD3 T-cell engaging bispecific antibody on maintenance of efficient tumor cell kill and cytokine release.
Journal of Clinical Oncology·2020· 1 cited
TNB383B.0001: A Multicenter, Phase 1, Open-Label, Dose-Escalation Andexpansion Study of TNB-383B, a Bispecific Antibodytargeting BCMA in Subjects with Relapsed or Refractorymultiple Myeloma
Blood·2019· 15 cited
TNB-486, a Novel Fully Human Bispecific CD19 x CD3 Antibody That Kills CD19-Positive Tumor Cells with Minimal Cytokine Secretion
Blood·2019· 6 cited
T Cells Expressing an Anti-B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor with a Fully-Human Heavy-Chain-Only Antigen Recognition Domain Induce Remissions in Patients with Relapsed Multiple Myeloma
Blood·2019· 45 cited
page 1 of 3Next →

Frequent Co-authors

Duy Pham(18), Ute Schellenberger(18), Nathan D. Trinklein(17), Kevin Dang(17), Harshad S. Ugamraj(17), Suhasini Iyer(16), Wim van Schooten(16), Katherine E. Harris(15), Starlynn Clarke(13), Shelley Force Aldred(13), Laura Davison(13), Andrew Boudreau(12), Udaya S. Rangaswamy(12), Brett Jorgensen(9), Roland Buelow(9), Aarti Balasubramani(9), Payal Pratap(8), Preethi Sankaran(7), Pranjali Dalvi(7), Andrew M. Scharenberg(6)